St. Louis, Missouri. Dr. Klein has reported that he has no relationships relevant to the contents of this paper to disclose. Although the investigators report that there was no difference in distal embolization with or without a filter, the event rate is too small to have detected a difference, and operators should consider placement of embolic protection for these procedures to truly "leave no trace."
Finally, the primary 1-year patency of treated vessels in claudicants (Duplex ultrasound peak systolic velocity ratio <2.4) was 78% overall, which is comparable to contemporary stent trials. Surprisingly, given the small caliber of these vessels, infrapopliteal vessels remained 90% patent at 1 year.
Additionally, noninferiority of this revascularization strategy in diabetic versus nondiabetic claudicants was demonstrated, which is interesting and demands future study. Limb preservation was achieved in 95% of cases in the CLI group, which exceeds most surgical studies (12, 13) .
Although all nonstent technologies lack large randomized data to support their use, proponents of directional atherectomy underscore the ability of this approach to preclude stenting; in this large registry, the overall stent bailout rate was 3.2%. In Table 8 of Overall, the DEFINITIVE LE trial suggests that directional atherectomy for the treatment of claudication and CLI is a promising "leave no trace" endovascular strategy, but we are still left with the need for randomized comparative data examining directional atherectomy versus stent therapy, that is, more definitive data, prior to fully embracing this technology in the periphery.
